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license (http://creativecommons.org/Summary Bone graft substitutes are commonly used to treat large bone defects, particularly
if they can additionally act as a local delivery system for therapeutic agents capable of
enhancing bone regeneration. In this study, composite scaffolds made of poly (lactic-co-glyco-
lic acid) (PLGA) and tricalcium phosphate (TCP) called P/T were fabricated by a low-
temperature rapid prototyping technique. In order to optimise the delivery system, two
different approaches for loading either the phytomolecule icaritin (ICT) or bone morphoge-
netic protein-2 (BMP-2) were developed for an in vivo efficacy study. One was an “incorpo-
rating approach” in which the growth factor was incorporated into the scaffold during
fabrication, whereas the other was a “coating approach” in which the fabricated scaffold
was immersed into a preparative solution containing the growth factor. Scaffolds incorporating
these growth factors were termed P/T/ICT and P/T/BMP-2, while scaffolds that had these
growth factors coated on to them were named, respectively, P/T þ ICT and P/T þ BMP-2. At of Orthopaedics & Traumatology, The Chinese University of Hong Kong, Hong Kong, China.
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92 S.-h. Chen et al.P/T scaffold without any loading was used as the control. The bone regeneration effect of
these scaffolds was compared in an ulnar bone defect model in rabbits. Bone regeneration
and angiogenesis was evaluated by high-resolution peripheral quantitative computed tomogra-
phy and magnetic resonance imaging postimplantation. Bone regeneration was better with the
P/T/ICT scaffolds with an 83.8% improvement compared with the control, and a 72.0%
improvement compared with the P/T/BMP-2 treatment. Although the P/T þ BMP-2 scaffold
demonstrated, as expected, the best overall bone regeneration, the P/T scaffold with incor-
porated ICT was shown to be an innovative and cost-effective bioactive scaffold which also
significantly enhanced bone regeneration with the potential to be validated for orthopaedic
applications.
Copyrightª 2014, The Authors. Published by Elsevier (Singapore) Pte Ltd. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Enhancing bone regeneration is highly desirable with regard
to repairing bone defects. Currently, the most commonly
used treatment strategy is an autograft or allograft repair.
However, the limitations of this approach include allograft
resorption, fracture, secondary infection, and a limited
supply of autografts [1,2]. Currently, bone graft sub-
stitutes, i.e., biomaterial scaffolds designed to enhance
bone regeneration, are widely used in bone tissue engi-
neering. Recent efforts have focused on the development
of biodegradable scaffolds that allow a controlled release
of bioactive ingredients. Endogenous osteoinductive growth
factors such as bone morphogenetic protein (BMP) [3] or
exogenous osteopromotive growth factors (such as small
phytomolecules) can help bone regeneration by either
incorporating them into or coating them onto to the surface
of porous composite scaffolds which are then implanted
into the bone defect to promote bone regeneration [4e6].
Current scaffold designs are hindered by unreliable delivery
of the bioactive component [7e9]. Issues that need to be
addressed are how to optimise the controlled release of the
bioactive ingredient over an extended therapeutic time
span and the effect on scaffold degradation kinetics after
in vivo implantation [5,10e14].
Synthetic polymer scaffolds are commonly used to
deliver growth factors with or without seeding cells to
enhance tissue healing and regeneration. Polymer-based
drug delivery systems can potentially optimise drug
loading, drug distribution as well as release kinetics
[12,15e17]. In our recent studies on such local delivery
systems, biocompatible poly (lactic-co-glycolic acid)
(PLGA) along with ceramic tricalcium phosphate (TCP)
facilitated not only pH buffering of the implant microen-
vironment, but also mechanically helped bone regeneration
though gradual degradation [18]. Therefore, these com-
pounds were selected as porous composite scaffolds for this
study [17,19].
When deciding on growth factors to incorporate into the
P/T scaffold, icaritin (ICT), an exogenous semisynthesised
single phytomolecule, was selected. ICT is formed after
intestinal metabolism of epimedium-derived flavonoids (EF)
and found in the serum [20,21] after oral administration of
a “bone strengthening Chinese herb” [22e24]. Our previous
study reported that ICT could enhance differentiation andproliferation of osteoblasts, facilitate matrix mineralisa-
tion, inhibit osteoclast activity and adipogenesis of
mesenchymal stem cells (MSCs) [20,25e27]. Because ICT
possesses chemical stability and has a strong binding
capability to oestrogen-receptor-beta due to a special
tertiary structure and molecular design for ligand-receptor
docking [28], we hypothesised that ICT could be incorpo-
rated or homogenised into porous composite scaffolds (P/
T/ICT) with preservation of bioactivity, molecular binding
activity and homogeneous distribution ensuring a controlled
release to enhance bone regeneration.
BMP-2, an endogenous growth factor, is well-known to
enhance bone regeneration both in vivo and when loaded
onto scaffold biomaterial [29e32]. Numerous biomaterials
have been tested to determine their potential to deliver
BMP-2 in a controlled sustained fashion to enhance bone
regeneration [30e32]. Whether incorporation of the
bioactive ingredient into the scaffold or coating it on the
surface of the scaffold best enhances bone regeneration,
needs to be investigated. In this study, scaffolds incorpo-
rated with ICT or synthesised BMP-2 are abbreviated as P/
T/ICT and P/T/BMP-2, respectively, whereas scaffolds
coated with ICT or BMP-2 are abbreviated as P/T þ ICT and
P/T þ BMP-2, respectively.
In our previous in vitro studies, P/T/ICT scaffolds were
found to be superior to both P/T control and P/T þ ICT
scaffold groups [7]. This was attributed to preservation of
ICT bioactivity and its sustained release from ICT incorpo-
rated scaffolds. In addition, P/T/ICT scaffolds also showed
desirable macroscopic and microscopic structure, biocom-
patibility, degradation rate, and mechanical property.
However, P/T/BMP-2 scaffolds did not seem to preserve
BMP-2 bioactivity as BMP-2 was denatured already during
scaffold preparation and fabrication with the presence of
organic solvents [7]. P/T þ BMP-2 scaffolds showed the best
bone regeneration capability as BMP-2 remained stable
after scaffold immersion into the coating solution.
Because tissue microenvironment, including pH, con-
centration of local inflammatory factors, fluid dynamics,
mechanical stresses, and cell responses will all influence
the implanted scaffold, it is desirable to evaluate the
in vivo bone regeneration potential of composite scaffolds
by comparing two different delivery approaches. Using an
animal model, we studied the effect of either incorporating
or coating scaffolds with both bioactive ingredients (ICT
PLGA/TCP composite scaffolds for bone regeneration 93and BMP-2) and implanting them into a fashioned bone
defect. New bone formation and tissue perfusion within the
defects were evaluated by radiography, three-dimensional
(3D) micro-computed tomography (CT), histology-based
optical imaging, and magnetic resonance imaging (MRI).
Materials and methods
Materials
PLGA [LA/GA Z 75/25, average molecular weights
MwZ 11.5  104, viscosityZ 1.67 dL/g (CHCL3/25 C)] was
purchased from Shandong Institute of Medical Instruments,
China. TCP (particle size of w30 mm) was purchased from
Beijing Modern Orient Precise Chemical Articles Co., Ltd,
China. Icaritin (ICT) was produced by Shanghai U-sea
Biotech Co., Ltd, China. rhBMP-2 freeze-dried powder was
produced by Shanghai Rebone Biomaterials Co., Ltd, China.
Preparation of P/T scaffolds with ICT or BMP-2
incorporating
The composite scaffolds were fabricated using a low-
temperature biological-material rapid-prototyping device
(3-D printer) (CLRF-2000-II, Tsinghua University, China) using
an established protocol [33]. Briefly, PLGA was added with a
powderweight to solution volume of 13:100 in organic solvent
1.4-dioxane. PLGA andTCP powderswith aweight ratio of 4:1
were dissolved to form a homogeneous solution, and then ICT
or BMP-2 powder were prepared as either 0.052:100 (powder
weight to solution volume) for the P/T/ICT group or as
0.013:100 (powder weight to solution volume) for the P/T/
BMP-2 group. Final homogenisation was undertaken to pre-
pare P/T scaffolds incorporating ICT or BMP-2 [34e36]. An
untreated P/T scaffold was used as the control group. The
homogenised paste was then sprayed by a computer-driven
nozzle and deposited layer-by-layer according to a prede-
signed model [37]. The temperature in the production
chamber was 28 C. Finally, the fabricated scaffolds were
freezedried (ChristAlpha1-2 LD,London,UK) toallowsolvent
vaporisation. The fabricated scaffolds possess around 75%
porosity and have amacropore size of 450 mm in diameter [7].
Preparation of P/T scaffolds with ICT or BMP-2
coating
Because coating is the conventionalmethod of loading BMP-2
or other growth factors onto the outer or inner surfaces of
scaffolds, we also prepared P/T scaffolds coated with ICT or
BMP-2 by immersing P/T scaffolds entirely into ICT or BMP-2
solutions. Thesewere knownas the P/Tþ ICTandP/TþBMP-
2 groups, respectively. The quantity of ICT or BMP-2-coated
onto P/Twas calculated to be similar to the quantity of ICTor
BMP-2 incorporated into the P/T scaffolds (Fig. 1).
Establishment of segmental ulnar bone defect in
rabbits
The Animal Experimental Ethics Committee (AEEC) of the
corresponding author’s institution approved the studyprotocol (Ref. no: 10/026/MIS-5). A segmental ulnar bone
defect model was established in 5-month-old New Zealand
whitemale rabbits weighing 3.5e4 kg based on our published
protocol [38,39]. Under general anaesthesia, after shaving
the skin, a 20-mm surgical incision was made to expose the
ulna. A 12-mm segment of mid-shaft ulna was removed using
an oscillating saw (Synthes; Mathys AG, Bettlach,
Switzerland) irrigated with saline. The scaffold was press-
fitted into the defect. Post-operative pain relief was
managed by three separate Temgesic injections for the first
72 h. Five types of implanted scaffold were tested. These
were the untreated P/T scaffold as control and four experi-
mental scaffolds, i.e. (1) P/T/ICT, (2) P/T/BMP-2, (3)
P/Tþ ICTand (4) P/TþBMP-2 (Fig. 1). Both forelimbs from48
rabbits were studied; i.e., 96 forelimbs. Of these 96 fore-
limbs, 60 underwent histological analysis with 30 forelimbs
selected for decalcified histology and 30 contralateral fore-
limbs for undecalcified histology for the five different groups
at Week 8. The remaining 36 forelimbs underwent angio-
genesis analysis as three P/T, P/T/ICT, and P/T/BMP-2
groups using micro-CT-based micro-angiography and MRI
perfusion analysis at Week 2 and Week 4 postsurgery.Evaluation of new bone formation within the bone
defect region
Radiography
High-resolution radiographs (Medical X-ray Film, Fuji Photo
Film Co., Ltd, Japan) of the ulnar defects were obtained
immediately after surgery and at Weeks 2, 4, and 8 post-
surgery using a commercial X-ray machine (Faxitron X-ray
Corporation, Wheeling, IL, USA), with an exposure time of 3 s
and tube voltage of 60 kVp. These radiographs were scanned
as TIF images using a Photo Scanner (Epson Perfection 4990,
Epson America Inc., Salt Lake City, Utah, USA). New bone
was quantified both by size and by calculation of the frac-
tional area of the original bone defect occupied by new bone
using Adobe photoshop CS5 software (Chicago, USA). New
bone formation with the bone defect was graded from 1 to 4
according to the amount of fractional new bone area with
0e25% (score  1); 25e50% (1  score  2); 50e75%
(2  score  3); and 75e100% (3  score  4) [40].
HR-pQCT
New bone deposition was also evaluated using three-
dimensional high-resolution peripheral quantitative
computed tomography (HR-pQCT) (XtremeCT, Scanco
Medical, Bru¨ttisellen, Switzerland) at 2, 4 and 8 weeks
postsurgery [41]. For HR-pQCT, the ulnar defect was scan-
ned at a spatial resolution of 40 mm. The bone component
was segmented from the marrow and soft tissue constitu-
ents by thresholding. A threshold 150 HU (Hounsfield
units) represented bony tissue; a threshold <150 HU rep-
resented bone marrow, soft tissue, and implanted com-
posite scaffold [42]. New bone within the ulnar defect was
quantified by bone mineral density (BMD), tissue volume
(TV), and bone volume (BV).
Decalcified histology
After HR-pQCT examination, the ulnar specimens were
fixed in 10% neutral-buffered formaldehyde for 3 days
Figure 1 Illustration of porous P/T scaffold preparation by either incorporating or coating phytomolecule icaritin or BMP-2. BMP-
2Z bone morphogenetic protein-2; ICTZ icaritin; PLGAZ poly (lactic-co-glycolic acid); P/TZ PLGA/TCP; P/T/BMP-2Z PLGA/
TCP/BMP-2; P/T þ BMP-2 Z PLGA/TCP þ BMP-2; P/T/ICT Z PLGA/TCP/icaritin; P/T þ ICT Z PLGA/TCP þ icaritin;
TCP Z tricalcium phosphate.
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dehydrated using an ethanol series, and embedded in
paraffin using an Embedding Center (Thermolyne Sybron,
Dubuque, IA, USA). Coronal paraffin sections of 5 mm
thickness were prepared of the ulna defect region using a
microtome (LEICA RM2165, Wetzlar, Germany). Serial sec-
tions were variously stained as described below for further
microscopic evaluation.
Haematoxylin and eosin (H&E) and Goldner’s Trichrome
staining
Sections with H&E and Goldner’s Trichrome staining were
digitalised into a microscopic system (LEICA MPS 60, Solms,
Germany) for both descriptive histology of new bone
regeneration and quantitative histomorphometry [43,44].
New bone area and total implant area within the defect
were quantified separately using an Image-pro Plus soft-
ware system (Media Cybernetics, Silver Spring, MD, USA)
[44]. Four serial sections from each specimen were aver-
aged for statistical analysis. Polarised microscopy was used
to study collagen alignment within mineralised bone tissue.
Undecalcified histology
Sequential fluorescence labelling was used to study bone
dynamic bone remodelling within the ulnar segmental bone
defects using our established protocol [45,46]. In brief, two
fluorescent dyes, xylenol orange (90 mg/kg body weight)and calcein green (10 mg/kg body weight; both Sigma-
eAldrich GmbH, Munich, Germany), were injected subcu-
taneously and sequentially into the rabbits at day 10 and
day 3 before euthanasia. Samples were fixed in 10% neutral-
buffered formaldehyde for 3 days. The fixed samples were
then dehydrated in alcohol of varying concentration, infil-
trated and cleared with xylene, and embedded in methyl
methacrylate (MMA, Merck-Schuchardt, Munich, Germany).
After hardening, mid-coronal sections of thickness 200 mm
using a saw microtome (LEICA SP1600, Leica Instruments,
Nussloch, Germany) were obtained. These sections were
then polished to 100 mm thickness by a polisher (PHOENIX
4000, BUEHLER Ltd., Du¨sseldorf, Germany) before digital-
isation using a fluorescence microscopic system (LEICA
Q500MC, Leica Cambridge Ltd., UK).
Fluorochromes are calcium-seeking molecules that bond
to mineralisation fronts at bone formation sites. The areas
of bone formation labelled with fluorochromes were
visualised and quantified by specific fluorescence micro-
scopy. Calcein green was positive with green colour at
480 nm excitation wavelength while xylenol orange was
positive with red colour at 560 nm excitation wavelength. A
mixture of calcein green/xylenol orange was positive with
green and red colour at 620 nm excitation wavelength. The
fractional area of bone formation was then calculated and
expressed as a ratio of the calcein green to xylenol orange
labelled areas [47]. Stevenel’s Blue staining was performed
PLGA/TCP composite scaffolds for bone regeneration 95after fluorescence observation. To further observe the
process from osteoblast activity to osteoid deposition to
bone mineralisation, Goldner’s Trichrome staining was
performed on undecalcified MMA 10-mm-thick sections
(LEICA SM2500E, Leica Instruments).
Evaluation of neovascularisation
Micro-CT-based micro-angiography
Microfil perfusion was conducted in the forelimbs of rab-
bits. Briefly, under deep general anaesthesia, the both
axillary arteries and veins were separated and cannulated
with scurf-needles linked to a pump apparatus (PHD 22/
2000, Harvard Apparatus, Holliston, MA, USA) with a flow
speed set at 20 mm/min [41]. The vasculature was flushed
with prewarmed heparinised saline (50 U/mL) [48] and
perfused with 10% neutral-buffered formalin for fixation
followed by a heparinised saline flush. Then the vasculature
was injected with a confected radiopaque silicone rubber
compound (Microfil MV-122, Flow Tech; Carver, MA, USA).
Thereafter, both forelimbs were harvested, fixed with 10%
buffered formalin for 3 days, and decalcified with 9% formic
acid for 4 weeks for further study by micro-CT and
microscopy.
The entire forelimb was scanned for micro-CT-based
micro-angiography and quantified for both vascular con-
nectivity and density using our established protocol [41].
The limb was fixed in a tube with its long axis perpendicular
to the micro-CT gantry (viva-40, SCANCO MEDICAL, Bru¨tti-
sellen, Switzerland). The scan was performed at a spatial
resolution of 36 mm per voxel with a 1024  1024 image
matrix [21,25]. For blood vessel segmentation, background
noise was removed using a low pass Gaussian filter
(Sigma Z 1.2, Support Z 2) with blood vessels being
defined at a threshold of 100.
New vessel density within implants was quantified in
5 mm paraffin sections under microscopy with 100
magnification. Four consecutive slices in each sample were
analysed with 10 regions per slice randomly selected. The
number of new vessels filled with microfil dye were counted
and averaged over the four slices and 10 regions.
Dynamic magnetic resonance imaging
The rabbits were anaesthetised at Weeks 2 and 4 for dy-
namic contrast-enhanced magnetic resonance imaging
(MRI) of the ulnar bone defect sites using a high-field 3T
superconducting system (ACS-NT Intera; Philips, The
Netherlands). A whole body volume radiofrequency coil was
used for signal transmitting and a commercially available
surface radiofrequency microcoil with a diameter of 4.7 cm
(Micro 4.7, Philips Medical Systems, Best, The Netherlands)
was placed close to the ulnar defect for signal receiving. A
T1-weighted fast spin echo coronal sequence (section
thickness 3 mm, intersection gap 1 mm, field of view of
120 mm, matrix of 256  128) was acquired through the
ulnar bone defect [41].
A bolus of gadopentetate dimeglumine (Magnevist;
Schering, Berlin, Germany) (0.8 mmol/kg/body weight) was
rapidly injected manually via an ear vein over a time span of
<1 s followed by a saline flush [41,49]. Dynamic scanning
started at the same time as contrast medium injection.
Signal intensity (SI) increase was measured in an operator-defined ellipse-like region-of-interest (ROI) in the mid-
portion of the ulnar bone defect. Signal intensity was
plotted against time as a timeeintensity curve (TIC) for
calculating one of the principal parameters of tissue perfu-
sion namely “maximum enhancement”. This was defined as
the maximum percentage increase (SImax  SIbase) in SI from
baseline (SIbase) [40] and is a measure of the amount of gad-
olinium entering the ROI tissues.
Statistical analysis
All quantitative data were presented as mean  standard
deviation. Differences in bone formation and vessel in-
growth between different scaffolds treatments were ana-
lysed based on one time point by one-way ANOVA test using
SPSS version 17.0 (SPSS, Chicago, IL, USA). Statistical sig-
nificance was set at p < 0.05.
Results
New bone formation within ulnar defect
New bone area fraction
Representative radiographs showhowbonedefects implanted
with P/Tscaffold alone underwent fairly homogeneous partial
bone regeneration (Fig. 2A). For P/T/ICT scaffolds, complete
osseous bridging between the bone ends was seen along the
radial margin extending approximately midway along the
defect. Mean percentage of newly formed bone filling the
segmental defect region was 48.7% for P/T group; 86.3%, and
50.7% respectively for P/T/ICT and P/T/BMP-2 groups; 54.7%
and 99.4% respectively for P/Tþ ICTand P/Tþ BMP-2 groups.
Radiographic grading scores (Fig. 2B) indicated that therewas
significantly more bone regeneration in the P/T þ BMP-2
(score: 4.0)andP/T/ICTscaffold (score:3.5)groupscompared
to the P/T (score: 1.95), P/T/BMP-2 (score: 2.0) andP/Tþ ICT
(score: 2.2) scaffold groups at week 8 postimplantation
(*p < 0.05, **p < 0.01, nZ 6).
New bone volume fraction and BMD
HR-pQCT (Fig. 3A) demonstrated new bone within the bone
defects at Week 2, Week 4, and Week 8 after scaffold im-
plantation similar to that seen on radiographs. At Week 2,
no significant difference in either BMD or BV/TV was found
between groups. At 4 weeks postimplantation, new bone
formation as quantified by BMD and BV/TV, was greatest in
the P/T þ BMP-2 and P/T/ICT group scaffold groups, less in
the P/T þ ICT and P/T/BMP-2 groups and lowest in the P/T
control group (*p < 0.05, **p < 0.01, n Z 6). Bone forma-
tion increased further by Week 8 in all groups when
compared to Week 4 (*p < 0.05).
Histological new bone fraction
At Week 2 postimplantation, the bone defect was primarily
composed of soft tissue callus with no appreciable miner-
alised bone regeneration evident. Scaffold pores were filled
with loose fibrous connective tissue. The newly formed
bone tissue became evident at Week 4 with limited bony
bridging along the radial border of the bone defect. At
Week 8, new bone in-growth into the implanted scaffold
pores was evident in all groups, suggesting good
Figure 2 (A) Representative radiographs of ulnar segmental defects with scaffold implantation at Week 0, Week 2, Week 4, and
Week 8 postimplantation. P/T/ICT scaffolds showed more bone filling in the defects compared with P/T, P/T þ ICT, and P/T/BMP-2
groups. The P/T þ BMP-2 scaffold group showed the most bone filling. (B) Mean scores of radiographs taken at Week 2, Week 4, and
Week 8 postimplantation. The P/T/ICT group showed more new bone filling in the bone defects than the P/T, P/T/BMP-2 and
P/T þ ICT groups (**p < 0.01, for comparison between P/T/ICT and P/T groups at each time-point, nZ 6). The P/T þ BMP-2 group
showed the most new bone filling (**p < 0.01, for comparison between P/T þ BMP-2 and P/T groups, n Z 6).
96 S.-h. Chen et al.osteoconductivity and biocompatibility of the scaffold
material. In vivo osteogenesis within the bone defects at
Week 8 is shown in Fig. 4A. Serial radiographs reveal how
new bone first originates at the resident bone edges from
where it proceeds first along the external margins of the
scaffold implant and then towards the centre of the scaf-
fold. Quantitative analysis (Fig. 4B) shows that at Week 8,
the P/T/ICT group had more new bone in the defect
compared to the P/T, P/T/BMP-2 and P/T þ ICT groups. The
P/T þ BMP-2 scaffold again showed the most new bone
formation (*p < 0.05, **p < 0.01, n Z 6).
At Week 8, the P/T/ICT scaffold group had more and
larger isolated new bone islands along the radial margins and
within the scaffolds pores. The newly formed bone within
the scaffold was seen to have remodelled towards mature
lamellar bone with osteocytes within lacunae embedded in
the bone matrix. Goldner’s Trichrome staining successfully
differentiated mineralised bone from non-mineralised
osteoid. Fig. 4C shows differentiated cuboidal osteoblasts
derived from BMSCs adsorbed in scaffold micro- and macro-
pores lining the surface of osteoid tissue alongside newly
mineralised bone tissue in which mature osteocytes reside.
Fluorescence microscopic images showed more fluores-
cence deposition in the P/T/ICT scaffold group compared tothe P/T, P/T/BMP-2 and P/T þ ICT scaffold groups, whereas
the most fluorescence deposition was shown in P/T þ BMP-2
scaffold group at Week 8 (Fig. 5A). There was a higher ratio
of Calcein green/Xylenol orange labelled area in P/T/ICT
scaffold treatment group compared with the P/T, P/T/BMP-
2, and P/T þ ICT scaffold groups, whereas the P/T þ BMP-2
scaffold group showed the highest ratio at Week 8
(*p < 0.05, **p < 0.01, n Z 6) (Fig. 5B). Stevenel’s Blue
staining showed yellowish-green stained osteoid tissue
surrounding the red-stained mineralised bone tissue with
hypertrophic chondrocytes intermingling with newly
differentiated osteogenic cells and participating in initial
bone formation (Fig. 5C). In addition, Goldner’s Trichrome
staining showed new bone formation as dark red staining
osteoblasts, red staining osteoid tissue and bluish-green
staining mineralised bone tissue. The presence of large
multinucleated osteoclasts on the mineralised bone surface
indicated the occurrence of bone remodelling.
New vessels in-growth within ulnar defect
Neovascularisation
3D analysis of neovascularisation within the bone defect
regions is demonstrated in Fig. 6A showing newly formed
Figure 3 (A) Representative HR-pQCT 3D images of ulnar segmental defects analysed at Week 2, Week 4, and Week 8 post-
implantation. The P/T/ICT group showed more new bone formation in the defects compared with the P/T, P/T þ ICT, and P/T/
BMP-2 groups. The P/T þ BMP-2 scaffold group showed the most bone formation. (B) Bone volume within the defects and BMD
in the implanted scaffolds evaluated by HR-pQCT at Week 2, Week 4, and Week 8 postimplantation. The P/T/ICT group showed
more new bone formation, new bone density, and relative new bone volume in defects compared with that of the P/T, P/T/BMP-2,
and P/T þ ICT groups (*p < 0.05 and **p < 0.01, for comparison between P/T/ICT and P/T group at each time-point, n Z 6). The
P/T þ BMP-2 group showed the best new bone formation (**p < 0.01, for comparison between P/T þ BMP-2 and P/T groups, nZ 6).
PLGA/TCP composite scaffolds for bone regeneration 97vessel-like structures of diameter 300 mm. More newly
formed vessels were observed in bone implanted with the
P/T/ICT scaffold compared to those implanted with the
P/T and P/T/BMP-2 scaffolds at Week 2 and 4 post-
implantation. Fig. 6B1 showed that in all groups new
vessel in-growth increased from Week 2, reached a peak
at Week 4 before decreasing at Week 8. Compared with
the P/T and P/T/BMP-2 scaffold groups, the P/T/ICT
scaffold group showed many more new vessels in terms of
total vessel volume within bone defects (*p < 0.05,
**p < 0.01, n Z 6; Fig. 6B1). Vessel number or density at
Week 2 and Week 4 postimplantation is shown in Fig. 6B2.
Newly formed vessels within the scaffold pores became
visible at Week 2 and increased at Week 4, with a sig-
nificant greater vessel density in the P/T/ICT scaffold
group than in the P/T and P/T/BMP-2 scaffold groups
(*p < 0.05, n Z 6).
Dynamic blood perfusion function
As a measure of tissue perfusion in the bone defect site,
maximum enhancement increased more in the P/T/ICT
scaffold group at Week 2 and Week 4 compared with the
P/T and P/T/BMP-2 scaffold groups (Fig. 7A and B).Discussion
Based on the basic concept of “Translational medicine in
orthopaedics” [50,51], this in vivo study was designed to
evaluate the bone regeneration potential of different
PLGA/TCP-based porous composite scaffolds in long bone
defects. These were tested in an established ulnar bone
segmental defect model in rabbits. Two different loading
approaches were used. An “incorporating approach” was
the one incorporating ICT or BMP-2 into a solvent homoge-
nous liquid before scaffold fabrication. A “coating
approach” involved immersing the fabricated scaffolds into
a preparative solution containing ICT or BMP-2 for 24 h. The
concentrations of ICT and BMP-2 selected for evaluation
were optimised by our previous study [7,52]. We used
in vivo radiographs, HR-pQCT and MRI and ex vivo histology
and histomorphometry analysis to quantify bone regener-
ation within the bone defect sites that were implanted with
different scaffolds. We found that P/T scaffolds incorpo-
rating ICT significantly enhanced bone regeneration
compared with P/T control scaffolds or a P/T scaffold
coated with ICT. These findings confirmed our hypothesis
that ICT could be incorporated into P/T composite scaffolds
Figure 4 Representative sagittal sections of decalcified bone from ulnar segmental defects. (A) H&E and Goldner’s Trichrome
stained sections at Week 8 showed more newly formed bone in the P/T/ICT group than the P/T, P/T þ ICT, and P/T/BMP-2 groups
(yellow *: new bone; blue #: scaffolds). (B) New bone area quantified at Week 8. In the P/T/ICT group, there was more newly
formed bone in the defects compared with that of the P/T, P/T/BMP-2, and P/T þ ICT groups (*p < 0.05 and **p < 0.01, compared
between P/T/ICT and P/T group, n Z 6). The P/T þ BMP-2 group showed the largest area of newly formed bone (**p < 0.01, for
comparison between the P/T þ BMP-2 and P/T groups, n Z 6). (C) H&E and Goldner’s Trichrome stained section at Week 8
demonstrated continuous bone formation characterised by differentiated cuboidal osteoblasts (blue arrows) lining the surface of
osteoid tissue (yellow arrows) surrounding newly formed mineralised bone tissue (white bar Z 200 mm, yellow bar Z 100 mm).
98 S.-h. Chen et al.with preservation of bioactivity to enhance bone regener-
ation in vivo [53]. A P/T scaffold coated with BMP-2 served
as a positive control and showed the best bone regenera-
tion potential attributed to the powerful anabolic effect of
BMP-2. However, P/T scaffolds incorporated with BMP-2 did
not show significantly better bone regeneration than P/T.
Our previous study reported that BMP-2 released from BMP-
2 incorporated scaffolds was not detectable, although it
could be detected from BMP-2-coated scaffolds by ELISA
assay in vitro [7]. It seems that recombinant human (rhBMP-
2) is unstable in some solvents deteriorating, for example,
in 50% dioxane with only 5% of rhBMP-2 being detectable
after 4 days [54]. However, this study shows that rhBMP-2-
coated after scaffold fabrication using a free-gelation
method does maintain its potential for bone regeneration
[54].
In two recently published studies from the authors’
group [7,52], the safety of P/T and P/T incorporating ICT or
BMP-2 was confirmed using in vitro BMSCs proliferation
testing. Both PLGA and TCP are used for clinical applica-
tions whereas ICT is an intestinal metabolite of EF found in
serum after oral administration [21,55]. Therefore, ICT and
BMP-2 can be regarded as biologically safe within a
reasonable concentration range [7]. At Week 4 and Week 8,ICT incorporated scaffold demonstrated better bone
regeneration than control scaffolds. Incorporating ICT into
P/T scaffold is feasible and shows promise in bone regen-
eration. BMP-2-coated scaffolds demonstrated an expected
high bone regeneration capability such that by Week 4, the
entire defects were almost filled with newly formed bone
while incorporated BMP-2 did not show this anticipated
effect. Similarly, ICT-coated scaffolds showed less bone
regeneration capability compared to ICT incorporated
scaffolds although this was slightly better than the P/T
control group, suggesting that ICT promotes bone regen-
eration through a unique sustainable release or degradation
of its efficient components as reported in our recent
in vitro study [7] and current in vivo experimental animal
study [52].
Histological and histomorphometric analysis showed that
compared to the P/T control group, ICT coating and BMP-2
incorporated groups showed more osteoid tissue, mineral-
ised bone tissue and mature lamellar bone than the ICT
incorporated scaffold group. Upregulated osteogenic genes
expression, such as osteocalcin, further demonstrated this
positive effect on bone regeneration. Florescence micro-
scopy revealed earlier and increased bone regeneration in
ICT incorporated scaffolds compared to the control P/T, ICT
Figure 5 Representative sagittal sections of undecalcified bone from ulnar segmental defects. (A) Fluorescent micrographs,
Steven’s Blue and Goldner’s Trichrome staining showed new bone formation in bone defects at Week 8. More fluorescent deposition
and stained newly formed bone tissue indicated more new bone formation and faster remodelling in the P/T/ICT than that in the
P/T group (yellow *: new bone; blue #: scaffolds). (B) Quantitative analysis of new bone formation within the bone defect at Week
8. There was more bone formation in the P/T/ICT group compared to the P/T, P/T/BMP-2, and P/T þ ICT groups (*p < 0.05 and
**p < 0.01 for comparison between P/T/ICT and P/T groups, nZ 6). The P/T þ BMP-2 group was the one with the most new bone
formation (**p < 0.01, for comparison between P/T þ BMP-2 and P/T groups, n Z 6). (C) Stevenel’s Blue staining indicated that
yellowish-green stained osteoid tissues (purple arrows) surrounding red-stained mineralised bone tissue and with hypertrophic
chondrocytes (white arrows) joining the cohort of newly differentiating osteogenic cells and participating actively in initial bone
formation. In addition, Goldner’s Trichrome staining showed dark red-stained osteoblasts (blue arrows), red-stained osteoid tissue
(purple arrows) and bluish-green stained mineralised bone tissue. In addition, osteoclasts (orange arrows) observed on the min-
eralised bone surface also participated in the bone remodelling process (white bar Z 200 mm, yellow bar Z 100 mm).
PLGA/TCP composite scaffolds for bone regeneration 99coating and BMP-2 incorporated groups at both Week 4 and
Week 8. As anticipated BMP-2 coating P/T scaffold consis-
tently showed the best bone regeneration for all outcome
measures [30,56,57].P/T composite scaffolds facilitated new bone in-
growth
Pore size and porosity of the scaffold are important
morphological properties to consider with regard to bone
regeneration [7,58e61]. Scaffolds with high porosity and
adequate pore size could facilitate bone and vessel in-
growth [60,61]. All scaffolds fabricated for this study
possessed a w450 mm macropore, w20 mm micropore sizeand w70% porosity. Micro-CT and histological results
showed that bone tissue and bone marrow penetrated into
the centre of scaffolds though the macropores. Thus all of
the scaffolds used may have facilitated bone in-growth.
Macropores more than 300 mm are known to improve bone
regeneration [61], whereas the numerous micropores
(5e20 mm) incorporated into the scaffolds could facilitate
cellecell interaction and nutrient transport [62].
Degradation rates and mechanical properties are also
important considerations [63,64]. Bioabsorbable and
biocompatible scaffolds have a range of degradation rates
compared with tissue growth rates that results in natural
tissue replacement without the long-term complications
associated with implants. The trabecular structure of
scaffolds provides mechanical support as well as adequate
Figure 6 (A) Representative micro-CT-based micro-angiography of vessels formed within the ulnar segmental defect region at
Week 2 and Week 4 after implantation. The obvious increase in vessel volume within the defects was present at Week 2 and Week 4,
with the P/T/ICT group showing more vessels than the P/T and P/T/BMP-2 groups. (B1) Quantitative analysis of new vessel volume
formed at Week 2, Week 4, and Week 8. The volume of new vessels peaked at Week 4 after implantation, with significantly higher
vessel volume in the P/T/ICT groups than the P/T and P/T/BMP-2 groups (*p < 0.05 and **p < 0.01, for comparison between P/T/
ICT and P/T groups at each time-point, n Z 6). (B2) Vessel number in implanted scaffolds within bone defects: significantly more
new vessel in-growth was found in the P/T/ICT group as compared with the P/T and P/T/BMP-2 groups (*p < 0.05, for comparison
between P/T/ICT and P/T groups, n Z 6; black bar Z 2 mm).
100 S.-h. Chen et al.space for tissue in-growth. In this study, in vivo degradation
rate analysis did not show accelerated scaffold degradation
with in-growth of new bone and a sustained macropore
structure evident in P/T/ICT scaffolds up to Week 8.
Although the percentage of residual scaffold material area
was significantly decreased by w34% at Week 8 post-
implantation, there was no significant difference in degra-
dation rate across all of the scaffold groups (Supplementary
Fig. S1). At Week 4 newly formed bone tissue was mainly
near the cut margins of the bone defect, whereas at Week
8, bone regeneration was also found in the centre of the
scaffold. This can be explained by BMSCs differentiating
into osteoblasts to form new bone initially adjacent to the
surrounding residual bone, where its macroporous structure
and progressive degradation may facilitate BMSC migration,
osteoid formation, and mineralisation [7].P/T/ICT composite scaffolds facilitated new bone
and new vessels in-growth
As an exogenous phytomolecule, ICT is known for its stable
phytochemical structure and osteogenic potential
[7,21,27]. ICT incorporated scaffolds showed better boneregeneration than both control scaffolds without loading
and ICT coating scaffolds. This may be explained by the
sustained release of ICT molecules from the incorporated
scaffolds with preserved bioactivity [7,26]. Conversely,
higher concentrations of ICT released from ICT coating
scaffolds do not appear to favour bone regeneration. These
findings are in line with our in vitro study which showed
that ICT incorporated scaffolds had better mechanical
properties and slower degradation compared with the
control and ICT-coated scaffolds [7]. Histological analysis
showed how the scaffold provided good mechanical support
up to 8 weeks [65]. At the same time, scaffold degradation
released ICT facilitating BMSC adhesion, proliferation,
migration, and differentiation.
However, in contrast to ICT incorporated scaffolds, BMP-
2 incorporated scaffolds did not show improved bone
regeneration. Although ICT is a small relatively stable
phytomolecule, readily dissolvable without denaturation in
organic reagents such as dioxane or DMSO [24,53], BMP-2,
as a protein molecule with a tertiary structure, is easily
denatured by microenvironment changes, such as temper-
ature and pH and is also denatured by solvents such as
dioxane as well as freezing and drying [54]. Also, the BMP-2
incorporated scaffold did not show either increased
Figure 7 (A) Timeeintensity curve from perfusion MR imaging acquired from segmental bone defect. (B) Perfusion parameter
“Maximum enhancement (%)” peaked at 2 weeks and decreased by 4 weeks.
PLGA/TCP composite scaffolds for bone regeneration 101mechanical strength or a slower degradation rate compared
with the control scaffold. For BMP-2-coated scaffolds,
preserved BMP-2 bioactivity facilitated bone regeneration
[30e32]. Angiogenesis is important for bone regeneration
[66]. In successful bone regeneration, vascularisation pre-
cedes osteogenesis [67], and enhanced neovascularisation
accelerates bone formation. Angiogenesis helps supply nu-
trients and oxygen and delivers critical biological stimuli for
osteogenic differentiation of MSCs. Growth factors such as
fibroblast growth factor (FGF), vascular endothelial growth
factor (VEGF) and BMP all facilitate angiogenesis [68].
Scaffold implant porosity can positively affect angiogenesis
with the interconnected pore structure favouring vascular
conduction and growth. In the present study, dynamic
contrast-enhanced MRI showed how good blood perfusion
was detected in bone defects at Week 2 and Week 4 post-
implantation coinciding with new vessel in-growth into the
scaffold macropores as seen on micro-CT-based micro-
angiography and 2D histological analysis. New vessel in-
growth peaked at 4 weeks and settled by 8 weeks. ICTincorporated scaffolds showed significantly more blood
vessel in-growth into the pores of the implanted scaffolds
during the early stages of bone regeneration compared with
control scaffolds. Although our in vitro study did not show a
direct angiogenic stimulatory effect of ICT [27], this in vivo
study indicates that an enhanced angiogenesis seen with
ICT incorporated scaffolds might be regulated indirectly via
by promoting osteogenesis though enhanced MSC recruit-
ment [69,70]. The likely cell signalling and molecular
mechanisms for this process require further investigation.
Sustained release of ICT from ICT incorporated scaffolds
could promote MSC migration with resultant angiogenesis
and osteogenesis. BMP-2 incorporated scaffolds did not
show enhanced angiogenesis. One of the main limitations of
this study is that we were not able to directly detect con-
centration of either local or serum ICT. Apart from perfu-
sion MR imaging we only were able to acquire limited data
on blood supply to the bone defect region and its role in
bone degeneration and scaffold degradation. The mecha-
nism of in vivo scaffold degradation together with the
102 S.-h. Chen et al.actual cellular mechanicals involved such as cell-material
matrix interaction should be further investigated. In addi-
tion, ICT- and BMP-2-coated scaffolds were initially
designed for comparable analysis for their osteogenic po-
tential, but not for further angiogenesis investigation.
Therefore we only focused on angiogenesis measurements
on ICT and BMP-2 incorporated scaffolds instead of for all
groups.
Conclusions
P/T scaffolds incorporating ICT significantly enhanced bone
regeneration compared with a P/T control scaffold and a P/
T scaffold coating ICT, although, as expected, a P/T com-
posite scaffold coated with BMP-2 had the best bone
regeneration effect. Conversely, the P/T/BMP-2 scaffold
only had limited bone regeneration potential, which can be
explained by denaturation of BMP-2 during scaffold prepa-
ration. P/T incorporated scaffolds are an innovative scaf-
fold material capable of enhancing bone regeneration with
potential clinical orthopaedic application.
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